Monte Rosa Therapeutics Inc (NASDAQ:GLUE) stock is trading higher on Monday after the company announced a global exclusive ...

Wedbush has recently initiated Monte Rosa Therapeutics Inc (GLUE) stock to Outperform rating, as announced on February 15, 2024, according to Finviz. Earlier, on January 3, 2023, Wells Fargo had ...

Key Takeaways Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the ...

Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.

TD Cowen analyst Marc Frahm has maintained their bullish stance on GLUE stock, giving a Buy rating on October 28. Marc Frahm has given his Buy ...

智通财经APP获悉，周一，Monte Rosa Therapeutics (GLUE.US)开盘大幅拉升，截至发稿，暴涨超63%，报7.98美元。消息面上，生物技术公司Monte Rosa Therapeutics与诺华制药 (NVS.US)签署了一项独家许可协议，以推进其用于自身免疫性疾病的VAV1导向的分子胶降解剂 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX – Research Report), Gossamer ...

Monte Rosa’s stock has demonstrated robust year-to-date performance, boasting an impressive +32.12% increase. For context, the S&P 500 has gained +22.32% in the same timeframe. This comparison ...

Discover why the U.S. economy is stronger than any President, regardless of political party. Click for market outlook ...

BOSTON (AP) — BOSTON (AP) — Monte Rosa Therapeutics Inc. (GLUE) on Thursday reported a loss of $23.9 million in its third quarter. The Boston-based company said it had a loss of 29 cents per share.

Monte Rosa Therapeutics, Inc. secures $150M partnership with Novartis for immune treatments. Click for my updated look at ...

生物技术公司Monte Rosa Therapeutics（GLUE.US）与 诺华 制药（NVS.US）签署了一项独家许可协议，以推进其用于自身免疫性疾病的VAV1导向的分子胶降解剂（MGD），包括MRT-6160。受此消息提振，Monte Rosa股价周一美股盘前一度大涨近50%。